Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in Nat Med Retrieve available abstracts of 29 articles: HTML format

Single Articles

May 2025
1. CASCONE T, Bonanno L, Guisier F, Insa A, et al
   Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.
   Nat Med. 2025 May 31. doi: 10.1038/s41591-025-03746.
   PubMed     Abstract available
   
   
   
2. SKOULIDIS F, Li BT, de Langen AJ, Hong DS, et al
   Molecular determinants of sotorasib clinical efficacy in KRAS(G12C)-mutated non-small-cell lung cancer.
   Nat Med. 2025 May 28. doi: 10.1038/s41591-025-03732.
   PubMed     Abstract available
   
   
   
3. ZHENG MM, Zhou Q, Chen HJ, Jiang BY, et al
   Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases.
   Nat Med. 2025;31:1547-1556.
   PubMed     Abstract available
   
   
   April 2025
4. ZHAO S, Cheng Y, Wang Q, Li X, et al
   Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials.
   Nat Med. 2025 Apr 10. doi: 10.1038/s41591-025-03638.
   PubMed     Abstract available
   
   
   March 2025
5. HERBST RS, John T, Grohe C, Goldman JW, et al
   Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.
   Nat Med. 2025 Mar 17. doi: 10.1038/s41591-025-03577.
   PubMed     Abstract available
   
   
   February 2025
6. TAGORE S, Caprio L, Amin AD, Bestak K, et al
   Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases.
   Nat Med. 2025 Feb 27. doi: 10.1038/s41591-025-03530.
   PubMed     Abstract available
   
   
   January 2025
7. SHI Y, Fang J, Xing L, Yao Y, et al
   Glecirasib in KRAS(G12C)-mutated nonsmall-cell lung cancer: a phase 2b trial.
   Nat Med. 2025 Jan 6. doi: 10.1038/s41591-024-03401.
   PubMed     Abstract available
   
   
   
8. BLACK JRM, Bartha G, Abbott CW, Boyle SM, et al
   Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma.
   Nat Med. 2025;31:70-76.
   PubMed     Abstract available
   
   
   
9. ZUCCATO JA, Mamatjan Y, Nassiri F, Ajisebutu A, et al
   Prediction of brain metastasis development with DNA methylation signatures.
   Nat Med. 2025;31:116-125.
   PubMed     Abstract available
   
   
   November 2024
10. ALBAN TJ, Riaz N, Parthasarathy P, Makarov V, et al
    Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab.
    Nat Med. 2024;30:3209-3222.
    PubMed     Abstract available
    
    
    
11. WANG C, Shao J, He Y, Wu J, et al
    Data-driven risk stratification and precision management of pulmonary nodules detected on chest computed tomography.
    Nat Med. 2024;30:3184-3195.
    PubMed     Abstract available
    
    
    September 2024
12. LI N, Wang SY
    Navigating treatment combinations in small-cell lung cancer.
    Nat Med. 2024 Sep 18. doi: 10.1038/s41591-024-03255.
    PubMed    
    
    
    
13. JEE J, Brannon AR, Singh R, Derkach A, et al
    DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism.
    Nat Med. 2024;30:2499-2507.
    PubMed     Abstract available
    
    
    August 2024
14. ROBICHAUX JP, Elamin YY, Tan Z, Carter BW, et al
    Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
    Nat Med. 2024 Aug 20. doi: 10.1038/s41591-024-03178.
    PubMed    
    
    
    July 2024
15. CHENG Y, Chen J, Zhang W, Xie C, et al
    Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial.
    Nat Med. 2024 Jul 11. doi: 10.1038/s41591-024-03132.
    PubMed     Abstract available
    
    
    June 2024
16. PETERS S, Gadgeel SM, Mok T, Nadal E, et al
    Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
    Nat Med. 2024 Jun 19. doi: 10.1038/s41591-024-03008.
    PubMed     Abstract available
    
    
    
17. WIDMAN AJ, Shah M, Frydendahl A, Halmos D, et al
    Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment.
    Nat Med. 2024;30:1655-1666.
    PubMed     Abstract available
    
    
    May 2024
18. SHIELDS MD, Lovly CM
    Refining neoadjuvant immunotherapy for resectable lung cancer.
    Nat Med. 2024 May 13. doi: 10.1038/s41591-024-03001.
    PubMed    
    
    
    
19. ZENG Y, Hu CH, Li YZ, Zhou JS, et al
    Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer.
    Nat Med. 2024 May 13. doi: 10.1038/s41591-024-02929.
    PubMed     Abstract available
    
    
    April 2024
20. SCHULER M, Cuppens K, Plones T, Wiesweg M, et al
    Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.
    Nat Med. 2024 Apr 30. doi: 10.1038/s41591-024-02965.
    PubMed     Abstract available
    
    
    
21. TAMMEMAGI MC, Darling GE, Schmidt H, Walker MJ, et al
    Risk-based lung cancer screening performance in a universal healthcare setting.
    Nat Med. 2024;30:1054-1064.
    PubMed     Abstract available
    
    
    
22. VAIDYA A, Chen RJ, Williamson DFK, Song AH, et al
    Demographic bias in misdiagnosis by computational pathology models.
    Nat Med. 2024;30:1174-1190.
    PubMed     Abstract available
    
    
    
23. SINGHAL A, Li BT, O'Reilly EM
    Targeting KRAS in cancer.
    Nat Med. 2024;30:969-983.
    PubMed     Abstract available
    
    
    
24. GHILARDI G, Fraietta JA, Gerson JN, Van Deerlin VM, et al
    T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
    Nat Med. 2024;30:984-989.
    PubMed     Abstract available
    
    
    February 2024
25. BESSE B, Pons-Tostivint E, Park K, Hartl S, et al
    Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
    Nat Med. 2024 Feb 13. doi: 10.1038/s41591-024-02808.
    PubMed     Abstract available
    
    
    October 2023
26. DEUTSCH JS, Cimino-Mathews A, Thompson E, Provencio M, et al
    Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
    Nat Med. 2023 Oct 30. doi: 10.1038/s41591-023-02660.
    PubMed     Abstract available
    
    
    
27. CHAFT JE, Oezkan F, Kris MG, Bunn PA, et al
    Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
    Nat Med. 2023 Oct 10. doi: 10.1038/s41591-023-02627.
    PubMed    
    
    
    
28. ANAGNOSTOU V, Ho C, Nicholas G, Juergens RA, et al
    ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
    Nat Med. 2023 Oct 9. doi: 10.1038/s41591-023-02598.
    PubMed     Abstract available
    
    
    September 2023
29. CHO BC, Kim DW, Spira AI, Gomez JE, et al
    Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.
    Nat Med. 2023 Sep 14. doi: 10.1038/s41591-023-02554.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.